NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Phenomix Sciences

Phenomix Sciences

Private
Menlo Park, CaliforniaHealthcare & Life Scienceshttps://www.phenomixsciences.com/

Last Round

Series A

Extension

Jan 7, 2026

Total Funding Raised

$12.3M

Company Overview

Phenomix Sciences is a biotechnology company that develops a data analysis platform for precision medicine in obesity management, featuring a novel blood test and an AI-driven algorithm to classify patients' unique pathophysiological phenotypes.

Sector

Healthcare & Life Sciences

Verticals

Precision Medicine, Biotechnology, Healthcare Analytics, Medical AI

Business Model

B2B2C

Customer Profile

Usage-Based SaaS, Services & Consulting

AI Layer

Application

Keywords

genetic testingprecision medicineweight loss treatmentobesity careobesity phenotypingGLP-1personalized weight lossGRSgenetic risk scorediagnostic testingclinical decision supportpersonalized medicinedigital healthmedtechbiohacking

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Phenomix Sciences Comparables

Compare Phenomix Sciences with similar companies based on industry and business-model similarity.

Phenomix Sciences comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
GB HealthWatch
76%
Digbi Health
71%
Nutrigenomix
70%

Phenomix Sciences Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series A ExtensionJan 7, 2026
Series AMay 16, 2024
GrantMay 16, 2024
GrantMar 15, 2024
SeedMar 22, 2021
Seed
Nov 16, 2018

Key People

Founding team and executive leadership

Mark Bagnall

Chief Executive Officer

Executive Team

Frank Grazzini

CFO

Executive Team

Liv Williamsen

Chief Operating Officer

Executive Team

Phenomix Sciences Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Nov 4, 2025

    MyPhenome test shows clinical utility in predicting obesity and treatment outcomes.

  • Nov 4, 2025

    Presented new research at Obesity Week 2025.

Phenomix Sciences Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Phenomix Sciences Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Phenomix Sciences's valuation, stock price, and market status.

Firmographic Details

HeadquartersMenlo Park, California
Employee Range16
Year Founded2017
Last FundingJan 7, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.